Stay updated on Pembrolizumab in Unresectable Squamous Skin Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Unresectable Squamous Skin Cancer Clinical Trial page.

Latest updates to the Pembrolizumab in Unresectable Squamous Skin Cancer Clinical Trial page
- ChecktodayChange DetectedA sitewide banner announces NIH website transition updates and says the agency is changing its terminology from “Artificial Intelligence” to “Super Intelligence.”SummaryDifference1%

- Check7 days agoChange DetectedThe footer’s site revision identifier advances from v3.7.1 to v3.7.2 on the 403 error page.SummaryDifference0.2%

- Check14 days agoChange DetectedThe site footer revision changes from v3.7.0 to v3.7.1, while the study record still displays a 403 Forbidden error.SummaryDifference0.2%

- Check35 days agoChange DetectedThe study page now displays a 403 Forbidden error instead of the study content for NCT02883556, indicating the record is currently inaccessible.SummaryDifference18%

- Check56 days agoChange DetectedAn NIH grant/contract note for 2016 was added to the page, and the site revision was updated to v3.6.6 (replacing the previous v3.6.5).SummaryDifference0.1%

- Check77 days agoChange DetectedRevision badge updated from v3.6.4 to v3.6.5, reflecting a minor deployment change. The study details themselves remain unchanged.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in Unresectable Squamous Skin Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Unresectable Squamous Skin Cancer Clinical Trial page.